A Retrospective Analysis of Risk Factors and Patient Outcomes of Bloodstream Infection with Extended-Spectrum β-Lactamase-Producing Escherichia coli in a Chinese Tertiary Hospital

References

• Al-Hasan MN, Lahr BD, Eckel-Passow JE, Baddour LM. Temporal trends in Enterobacter species bloodstream infection: a population-based study from 1998–2007. Clin Microbiol Infect. 2011;17(4):539–545. doi:10.1111/j.1469-0691.2010.03277.x20518795
   PubMed Web of Science ®Google Scholar
• Allocati N, Masulli M, Alexeyev MF, Di Ilio C. Escherichia coli in Europe: an overview. Int J Environ Res Public Health. 2013;10(12):6235–6254. doi:10.3390/ijerph1012623524287850
   PubMed Web of Science ®Google Scholar
• Blot K, Hammami N, Blot S, Vogelaers D, Lambert ML. Increasing burden of Escherichia coli, Klebsiella pneumoniae, and Enterococcus faecium in hospital-acquired bloodstream infections (2000–2014): a national dynamic cohort study. Infect Control Hosp Epidemiol. 2019;40(6):705–709. doi:10.1017/ice.2019.5931012402
   PubMed Web of Science ®Google Scholar
• Lee H, Yoon EJ, Kim D, et al. Antimicrobial resistance of major clinical pathogens in South Korea, May 2016 to April 2017: first one-year report from Kor-GLASS. Euro Surveill. 2018;23(42):1800047. doi:10.2807/1560-7917.ES.2018.23.42.1800047
   PubMedGoogle Scholar
• Gagliotti C, Balode A, Baquero F, et al. Escherichia coli and Staphylococcus aureus: bad news and good news from the European antimicrobial resistance surveillance network (EARS-Net, formerly EARSS), 2002 to 2009. Euro Surveill. 2011;16(11):19819. doi:10.2807/ese.16.11.19819-en21435327
   PubMedGoogle Scholar
• Thaden JT, Fowler VG, Sexton DJ, Anderson DJ. Increasing incidence of extended-spectrum β-lactamase-producing Escherichia coli in community hospitals throughout the Southeastern United States. Infect Control Hosp Epidemiol. 2016;37(1):49–54. doi:10.1017/ice.2015.23926458226
   PubMed Web of Science ®Google Scholar
• Kassakian SZ, Mermel LA. Changing epidemiology of infections due to extended spectrum beta-lactamase producing bacteria. Antimicrob Resist Infect Control. 2014;3(1):9. doi:10.1186/2047-2994-3-924666610
   PubMed Web of Science ®Google Scholar
• Hu FP, Guo Y, Zhu DM, et al. Resistance trends among clinical isolates in China reported from CHINET surveillance of bacterial resistance, 2005–2014. Clin Microbiol Infect. 2016;22(Suppl 1):S9–14. doi:10.1016/j.cmi.2016.01.00127000156
   PubMed Web of Science ®Google Scholar
• Tian X, Sun S, Jia X, Zou H, Li S, Zhang L. Epidemiology of and risk factors for infection with extended-spectrum beta-lactamase-producing carbapenem-resistant Enterobacteriaceae: results of a double case-control study. Infect Drug Resist. 2018;11:1339–1346. doi:10.2147/IDR.S17345630214254
   PubMed Web of Science ®Google Scholar
• Schwaber MJ, Navon-Venezia S, Schwartz D, Carmeli Y. High levels of antimicrobial coresistance among extended-spectrum-beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2005;49(5):2137–2139. doi:10.1128/aac.49.5.2137-2139.200515855548
   PubMed Web of Science ®Google Scholar
• Morosini MI, Garcia-Castillo M, Coque TM, et al. Antibiotic coresistance in extended-spectrum-beta-lactamase-producing Enterobacteriaceae and in vitro activity of tigecycline. Antimicrob Agents Chemother. 2006;50(8):2695–2699. doi:10.1128/aac.00155-0616870760
   PubMed Web of Science ®Google Scholar
• Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev. 2005;18(4):657–686. doi:10.1128/CMR.18.4.657-686.200516223952
   PubMed Web of Science ®Google Scholar
• Yang R, Zhu S, Pischke SE, Haugaa H, Zou X, Tonnessen TI. Bile and circulating HMGB1 contributes to systemic inflammation in obstructive jaundice. J Surg Res. 2018;228:14–19. doi:10.1016/j.jss.2018.02.04929907203
   PubMed Web of Science ®Google Scholar
• Lupp C, Robertson ML, Wickham ME, et al. Host-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of Enterobacteriaceae. Cell Host Microbe. 2007;2(3):204. doi:10.1016/j.chom.2007.08.00218030708
   PubMed Web of Science ®Google Scholar
• Iacob S, Iacob DG. Infectious threats, the intestinal barrier, and its Trojan horse: dysbiosis. Front Microbiol. 2019;10:1676. doi:10.3389/fmicb.2019.0167631447793
   PubMed Web of Science ®Google Scholar
• Willmann M, Vehreschild M, Biehl LM, et al. Distinct impact of antibiotics on the gut microbiome and resistome: a longitudinal multicenter cohort study. BMC Biol. 2019;17(1):76. doi:10.1186/s12915-019-0692-y31533707
   PubMed Web of Science ®Google Scholar
• Piewngam P, Quiñones M, Thirakittiwatthana W, Yungyuen T, Otto M, Kiratisin P. Composition of the intestinal microbiota in extended-spectrum β-lactamase-producing Enterobacteriaceae carriers and non-carriers in Thailand. Int J Antimicrob Agents. 2019;53(4):435–441. doi:10.1016/j.ijantimicag.2018.12.00630578963
   PubMed Web of Science ®Google Scholar
• Shi SH, Zhai ZL, Zheng SS. Pyogenic liver abscess of biliary origin: the existing problems and their strategies. Semin Liver Dis. 2018;38(3):270–283. doi:10.1055/s-0038-166136330041279
   PubMed Web of Science ®Google Scholar
• Frakking FN, Rottier WC, Dorigo-Zetsma JW, et al. Appropriateness of empirical treatment and outcome in bacteremia caused by extended-spectrum-β-lactamase-producing bacteria. Antimicrob Agents Chemother. 2013;57(7):3092–3099. doi:10.1128/aac.01523-1223612198
   PubMed Web of Science ®Google Scholar
• Stupica D, Lusa L, Klevišar MN, et al. Should we consider faecal colonisation with extended-spectrum β-lactamase-producing Enterobacteriaceae in empirical therapy of community-onset sepsis? Int J Antimicrob Agents. 2017;50(4):564–571. doi:10.1016/j.ijantimicag.2017.06.01928711676
   PubMed Web of Science ®Google Scholar
• Prasada S, Bhat A, Bhat S, Shenoy Mulki S, Tulasidas S. Changing antibiotic susceptibility pattern in uropathogenic Escherichia coli over a period of 5 years in a tertiary care center. Infect Drug Resist. 2019;12:1439–1443. doi:10.2147/idr.s20184931239723
   PubMed Web of Science ®Google Scholar
• Prevel R, Boyer A, M’Zali F, et al. Extended spectrum beta-lactamase producing Enterobacterales faecal carriage in a medical intensive care unit: low rates of cross-transmission and infection. Antimicrob Resist Infect Control. 2019;8:112. doi:10.1186/s13756-019-0572-931333839
   PubMed Web of Science ®Google Scholar
• Braunschweig CL, Levy P, Sheean PM, Wang X. Enteral compared with parenteral nutrition: a meta-analysis. Am J Clin Nutr. 2001;74(4):534–542. doi:10.1093/ajcn/74.4.53411566654
   PubMed Web of Science ®Google Scholar
• Pritchard C, Duffy S, Edington J, Pang F. Enteral nutrition and oral nutrition supplements: a review of the economics literature. JPEN J Parenter Enteral Nutr. 2006;30(1):52–59. doi:10.1177/01486071060300015216387900
   PubMed Web of Science ®Google Scholar
• Pitout JD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis. 2008;8(3):159–166. doi:10.1016/s1473-3099(08)70041-018291338
   PubMed Web of Science ®Google Scholar
• Peleg AY, Hooper DC. Hospital-acquired infections due to gram-negative bacteria. N Engl J Med. 2010;362(19):1804–1813. doi:10.1056/NEJMra090412420463340
   PubMed Web of Science ®Google Scholar
• Harris PN, Tambyah PA, Paterson DL. β-lactam and β-lactamase inhibitor combinations in the treatment of extended-spectrum β-lactamase producing Enterobacteriaceae: time for a reappraisal in the era of few antibiotic options? Lancet Infect Dis. 2015;15(4):475–485. doi:10.1016/s1473-3099(14)70950-825716293
   PubMed Web of Science ®Google Scholar